TD Cowen says the reaction to Eli Lilly’s (LLY) Phase IIb trial data of peresolimab in RA “seems excessive,” as there were n=2 malignancies in each of the 1000/400mg pereso groups vs. 0% in placebo through week 12 and an additional n=4 through week 60. The firm says AnaptysBio (ANAB) management reiterated that rosnilimab’s profile remains clean and that there have been no reports of any malignancies in any trial. The firm has a Buy rating on AnaptysBio shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- AnaptysBio price target raised to $20 from $18 at UBS
- AnaptysBio’s Promising Pipeline and Financial Stability Justify Buy Rating
- AnaptysBio price target raised to $45 from $40 at Wedbush
- Promising Clinical Trial Results and Strategic Growth Potential Drive Buy Rating for AnaptysBio
- AnaptysBio Reports Q2 2025 Financial Results and Updates